&w=3840&q=100)
Emcure Pharma hits 10% upper circuit; gains 20% in three days; here's why
Emcure Pharmaceuticals shares were locked in a 10 per cent upper circuit on Friday, May 23, 2025. The stock extended rally for the third consecutive session and gained nearly 20 per cent. The buying on the counter came after the company released its Q4 results.
At 12:27 PM, Emcure Pharma share price was up 10 per cent at ₹1,288.65 per share on the BSE. In comparison, the BSE Sensex was up 0.97 per cent at 81,734.05. The market capitalisation of the company stood at ₹24,417.77 crore. The 52-week high of the stock was at ₹1,577.5 per share and the 52-week low of the stock was at ₹890 per share.
Emcure Pharmaceutical Q4 profit growth
The company released its Q4 results on Thursday, after market hours. In the fourth quarter (Q4FY25) pharma company's net profit stood at ₹197.2 crore as against ₹121 crore, up 62 per cent.
Its revenue from operations in Q4 came in at ₹2,116.2 crore as compared to ₹1,771.3 crore a year ago, up 19 per cent.
Emcure Pharma dividend
The company's board recommended a final dividend of ₹3 per equity share of ₹10 /- (Rupees Ten only) each of the company (at the rate of 30 per cent) for the financial year ended March 31, 2025.
Emcure Pharma acquisition
The board also approved the incorporation of company arm Emcure Generics Private Limited.
"We would like to inform that the board of directors of the company in their meeting held today i.e. May 22, 2025, has inter-alia approved the incorporation of a wholly-owned Subsidiary by the name 'Emcure Generics Private Limited' in Pune, Maharashtra, India," the filing read.
About Emcure Pharmaceuticals
Emcure Pharma has over 350 brands, five research and development (R&D) centers, and 13 manufacturing facilities established across the country, outside India, it has a wide network across 70 countries. The company's API facilities ensure that the supply chain is vertically integrated providing flexibility over control of manufacturing. The company's core strength and competitive advantage lie in its established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 biologics in the domestic market and RoW markets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
8 minutes ago
- Mint
₹12 to ₹870: Multibagger penny stock turns ₹1 lakh into ₹72 lakh in five years
Multibagger penny stock: Amid volatility in the stock market, investors are often on the lookout for stocks which will give favourable returns. However, amid the ongoing global jitters, it is difficult to find such stocks; therefore, we bring you the share price journey of multibagger penny stock - Aayush Art and Bullion. Aayush Art and Bullion, which was once priced at ₹ 12 in August 2020, is now trading at ₹ 870 on the BSE. To put it in perspective, an investment of ₹ 1 lakh made five years ago in the stock and held over time would have grown significantly to nearly ₹ 72 lakh. The multibagger penny stock Aayush Art and Bullion opened at ₹ 870 on June 11, as compared to the previous close at ₹ 863.40 apiece. The multibagger stock has proven to be a wealth-creating machine for its long-term investors by surging over 7,101.67 per cent in five years. In the past one year, the multibagger penny stock has maintained its positive trajectory. Aayush Art and Bullion share price has risen as much as 673.68 per cent in one year. The stock has managed to impress the short-term investors, too. Aayush Art and Bullion shares ascended over 60 per cent in six months. In terms of year-to-date (YTD) performance, the scrip has gained over 23 per cent since the beginning of 2025, rising from ₹ 703.40 to the current market level. Aayush Art and Bullion Ltd reported a strong performance for the second half of FY25, signalling its most profitable phase yet. For H2 FY25, the company posted a net profit of ₹ 1.56 crore, a substantial jump from ₹ 24 lakh reported in H1 FY25. This turnaround in profitability underlines the company's strategic initiatives and improved operational efficiency. Overall, for FY25, the company registered a net profit of ₹ 1.81 crore, nearly seven times higher than the ₹ 26 lakh it reported in FY24, with earnings per share (EPS) rising sharply to ₹ 1.81 from ₹ 0.21 in the previous fiscal. The company's revenue from operations also witnessed exponential growth, reaching ₹ 73.77 crore in FY25 — a tenfold increase from ₹ 7.33 crore in FY24. This dramatic surge in topline performance is a result of robust demand in its core business segments and the successful execution of its long-term growth strategies.
Mint
29 minutes ago
- Mint
Indian benchmarks close marginally higher, led by IT; financials cap gains
(Updates for markets close) June 11 (Reuters) - India's benchmark indexes inched higher on Wednesday, led by IT stocks on signs of progress in trade talks between the U.S. and its key trading partners, such as India and China, while profit booking in financials capped gains. The Nifty 50 rose 0.15% to 25,141.4 and the BSE Sensex added 0.15% to 82,515.14. Negotiators from the U.S. and China have agreed on a framework to get their trade truce back on track, pending final approval by their countries' leaders. Other Asian markets rose on the day, with the MSCI Asia ex-Japan index gaining 0.6%. Meanwhile, Indian and U.S. officials made progress on bilateral trade talks in New Delhi, focusing on industrial goods, agriculture, tariff reductions and non-tariff barriers, according to Indian government sources. Seven of the 13 major sectors logged gains. IT companies, which earn a significant share of their revenue from the U.S., rose 1.3%, logging gains for a sixth straight session. However, pressure on financials and banks , down 0.3% each, capped broader market gains as profit-booking persisted due to the recent record highs that came in the wake of the RBI's steep rate cut. "There can be a consolidation in markets after the fast and furious rally in the last few weeks, but the trajectory for domestic markets remains upwards," said Devang Mehta, director of equity advisory at Spark Capital PWM, citing growth support from the RBI on Friday and the positivity around the global trade talks. India's Nifty 50 has gained 3.3% since the start of May and is trading at its highest level since mid-October 2024. Among other stocks, liquor makers such as Radico Khaitan and United Spirits lost 3.8% and 6.6% after Maharashtra state hiked excise duty on Indian Made Foreign Liquor. BSE fell 4.1% after being placed under a National Stock Exchange framework, drawing a 100% margin on trades. The broader, more domestically focussed small-caps and mid-caps fell about 0.5% each, snapping seven-session and five-session winning streaks, respectively. ($1 = 85.4750 Indian rupees) (Reporting by Bharath Rajeswaran in Bengaluru; Editing by Janane Venkatraman and Sumana Nandy)
Deccan Herald
35 minutes ago
- Deccan Herald
Rupee rises 6 paise to settle at 85.51 against US dollar
In the domestic equity market, the 30-share BSE Sensex rose 123.42 points to end at 82,515.14, while the Nifty rose 37.15 points to 25,141.40.
